Current Approaches for New TB Drugs

ISSN: 1875-6387 (Online)
ISSN: 1573-398X (Print)

Volume 13, 4 Issues, 2017

Download PDF Flyer

Current Respiratory Medicine Reviews

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Joseph Varon
The University of Texas Health Science Center
Houston, TX

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current Approaches for New TB Drugs

Current Respiratory Medicine Reviews, 10(2): 88-96.

Author(s): Shilpika Pandey, Isha Soni, Neha Topno, Arunava Dasgupta and Sidharth Chopra.

Affiliation: Division of Microbiology, CSIR-Central Drug Research Institute, B.S. 10/1, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow - 226031, India.


Tuberculosis is essentially a curable disease but inspite of a WHO approved DOTS therapy, it still continues to ravage mankind. This situation is exacerbated by long course of chemotherapy, increasing drug resistance and co-emergence with HIV. The TB drug pipeline remained stagnant for a long time with no new drug approved till FDA approval for Bedaquiline. This situation has now improved with a number of agents in pre-clinical and clinical development against M. tuberculosis. In this review, we are focusing on some of the newer drugs in discovery and preclinical development against M. tuberculosis.


Clinical strains, drugs, MIC, Mycobacterium, pre-clinical development, tuberculosis.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 10
Issue Number: 2
First Page: 88
Last Page: 96
Page Count: 9
DOI: 10.2174/1573398X10666140813201210
Price: $58
13th Asthma & COPD

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science